PDS Biotechnology Corp
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
PDSB$1.23+5.1%Stored close · as of Nov 6, 2026
Contents
Item 1. Condensed Consolidated Balance Sheets
Balance Sheets
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS · (unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $5,596,254 | $26,711,969 |
| Prepaid expenses and other assets | 1,448,939 | 1,542,116 |
| Total current assets | 7,045,193 | 28,254,085 |
| Noncurrent assets: | ||
| Prepaid expenses | 1,548,580 | 1,996,300 |
| Property and equipment, net | 176,612 | 120,184 |
| Financing lease right-to-use assets | 36,828 | 123,514 |
| Total assets | $8,807,213 | $30,494,083 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $6,393,967 | $3,574,448 |
| Accrued expenses | 1,629,313 | 742,227 |
| Current portion of debt | 4,322,500 | 5,130,372 |
| Financing lease obligation-short term | 31,696 | 36,167 |
| Total current liabilities | 12,377,476 | 9,483,214 |
| Noncurrent liabilities: | ||
| Debt, net of debt discount | - | 11,733,350 |
| Financing lease obligation-long term | 9,476 | 25,686 |
| Total liabilities | $12,386,952 | $21,242,250 |
| Commitments and contingencies (Note 9) | - | - |
| STOCKHOLDERS’ EQUITY | ||
| Common stock, $0.00033 par value, 150,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 55,921,806 and 54,878,233 issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 18,455 | 18,111 |
| Additional paid-in capital | 230,107,941 | 225,840,226 |
| Accumulated deficit | (233,706,135) | (216,606,504) |
| Total stockholders’ equity | (3,579,739) | 9,251,833 |
| Total liabilities and stockholders’ equity | $8,807,213 | $30,494,083 |
Index
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.